Document is current

Article History

Received: 15 June 2024

Accepted: 22 July 2024

First Online: 9 August 2024

Declarations

:

: Phillip J. Mease: research grants from AbbVie, Acelyrin, Amgen, BMS, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; consultancy fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Moonlake Pharma, Novartis, Pfizer, Sun Pharma, Takeda, UCB, and Ventyx Pharma; speakers bureaus from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB Pharma. Richard B. Warren: supported by the Manchester NIHR Biomedical Research Centre; consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, BMS, Boehringer Ingelheim, Celgene, DICE Therapeutics, Eli Lilly, GSK, Janssen, LEO Pharma, Meiji Pharma, Novartis, Pfizer, RAPT Therapeutics, Sanofi, Sun Pharma, UCB Pharma, and Union; research grants to his institution from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB Pharma; and honoraria from AbbVie, Almirall, BMS, Eli Lilly, Galderma, Janssen, and Novartis. Peter Nash: research grants, clinical trials, and honoraria for advice and lectures on behalf of AbbVie, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos/Gilead, GSK, Janssen, Novartis, Pfizer, Samsung, and UCB Pharma. Jean-Marie Grouin: consulting fees and honoraria from Acticor, Chugai, BeiGene, Inflectis, Inotrem, Ipsen, Janssen, Otsuka, SpikImm, and UCB Pharma. Nikos Lyris, Vanessa Taieb, Jason Eells: employees and shareholders of UCB Pharma. Iain B. McInnes: consulting fees and honoraria from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Cabaletta, Causeway Therapeutics, Celgene, Evelo, Janssen, Novartis, Eli Lilly, Moonlake, and UCB Pharma; research support from BMS, Boehringer Ingelheim, Celgene, Janssen, Novartis, and UCB Pharma.

: BE OPTIMAL and BE COMPLETE were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Guidance for Good Clinical Practice. Ethical approval was obtained from the relevant institutional review boards at participating sites, and all patients provided written informed consent in accordance with local requirements. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.